Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial.

Bouvier A, Hamel J-F, Delaunay J, Delabesse E, Dumas P-Y, Ledoux MPierre, Peterlin P, Luquet I, Guepin GRoth, Bulabois CEric, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial. Eur J Haematol. 2021.